BAY CITY CAPITAL LLC 4
4 · Kezar Life Sciences, Inc. · Filed Jun 28, 2018
Insider Transaction Report
Form 4
BAY CITY CAPITAL LLC
10% Owner
Transactions
- Conversion
Common Stock
2018-06-25+472,229→ 472,229 total(indirect: See Footnotes) - Purchase
Common Stock
2018-06-25$15.00/sh+150,000$2,250,000→ 622,229 total(indirect: See Footnotes) - Conversion
Series B Redeemable Convertible Preferred Stock
2018-06-25−472,229→ 0 total(indirect: See Footnotes)→ Common Stock (472,229 underlying)
Footnotes (3)
- [F1]Each share of Series B Redeemable Convertible Preferred Stock was convertible into one share of Common Stock at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering.
- [F2]Bay City Capital LLC, a Delaware limited liability company (BCC), Bay City Capital JV Management I LLC, a Delaware limited liability company (Management I), Bay City Capital GF XINDE Investment Management Co., a Cayman Islands company (Management Co.), and Bay City Capital GF Xinde International Life Sciences USD Fund, L.P., a Cayman Islands exempt limited partnership (USD Fund) are deemed to be a group for the purposes of Section 13(d) under the Securities Exchange Act of 1934. Management Co. is the general partner of USD Fund and has voting and dispositive power with respect to the securities held by USD Fund. BCC is the manager of, and an advisor to, Management I, and Management I holds an equity interest in Management Co.
- [F3]Represent securities held by USD Fund, including indirect interests of BCC, Management I, and Management Co. BCC, Management I and Management Co. each disclaims beneficial ownership with respect to these securities, except to the extent of their pecuniary interest therein.